AAO research
When Commercial Success Is Weak: How Strong Judging, Original Contributions, and Scholarly Articles Can Sustain an EB‑1A Petition
The decision offers a clear evidence lesson about sustaining an EB‑1A petition without solid commercial‑success proof, but lacks a distinct profession or unique criterion mix to merit a standalone page.
The AAO’s April 2018 decision APR042018_01B2203 presents a clear evidence lesson for applicants whose commercial success documentation falls short but who have strong work in other areas.
The Evidence Presented
The petitioning scientist presented several key pieces of evidence:
Patent inventor listings for multiple inventions
Development of specific technologies, including "a bifunctional ruthenium catalyst and hydrogen storage work"
Evidence of commercialization (though the AAO flagged this as uncertain)
A scholarly article that received a journal cover feature
Publications with high citation levels
Documentation showing independent manuscript review requests
These constitute solid evidence for original contributions, scholarly articles, and potentially judging—depending on how broadly "judging" is interpreted to include evaluation of peer work.
What the AAO Found Missing
The petition failed specifically in demonstrating commercial success. The AAO noted that:
> "While the petitioner provided patent inventor listings and some evidence of commercialization, this documentation was insufficient to establish that the inventions had achieved significant commercial impact."
Importantly, the AAO flagged the commercial success evidence as potentially falsified or unreliable, significantly weakening its credibility.
How Three Criteria Still Worked
Despite the weak commercial success finding, the petition satisfied three of the ten EB‑1A criteria:
Original Contributions: The development work and patents demonstrated original contributions of major significance
Scholarly Articles: The journal cover feature and high citation publications supported this criterion
Judging: Evidence suggesting peer evaluation or review activities
The AAO accepted these three areas as sufficient to meet the "exceptional ability" threshold.
Practical Takeaways for Applicants
This decision offers concrete guidance:
Commercial success is not mandatory—even when weak, strong evidence in other areas can sustain a petition
Original contributions and scholarly articles are particularly valuable when commercial success documentation is lacking or questionable
Judging work of others remains relevant, especially for scientists and researchers
The common mistake applicants make here is assuming that strong performance in other criteria somehow compensates for weak commercial success—a misunderstanding the AAO explicitly corrected.
Source Note
Non-precedent AAO decisions are used as evidence examples. They are not binding authority and do not predict any individual case.